1-19 of 19
Peter C. Adamson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Jennifer H. Foster, Stephan D. Voss, David C. Hall, Charles G. Minard, Frank M. Balis, Keith Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yael P. Mossé
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3543–3548.
https://doi.org/10.1158/1078-0432.CCR-20-4224
Published: 01 July 2021
View article titled, Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Open the PDF for Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) in another window
Includes: Supplementary data
Journal Articles

AACR Cancer Progress Report 2014

Carlos L. Arteaga, Peter C. Adamson, Jeffrey A. Engelman, Margaret Foti, Richard B. Gaynor, Susan G. Hilsenbeck, Paul J. Limburg, Scott W. Lowe, Elaine R. Mardis, Scott Ramsey, Timothy R. Rebbeck, Andrea L. Richardson, Eric H. Rubin, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19_Supplement): S1–S112.
https://doi.org/10.1158/1078-0432.CCR-14-2123
Published: 01 October 2014
View article titled, AACR Cancer Progress Report 2014
Open the PDF for AACR Cancer Progress Report 2014 in another window
Includes: Supplementary data
Journal Articles

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

Chand Khanna, Timothy M. Fan, Richard Gorlick, Lee J. Helman, Eugenie S. Kleinerman, Peter C. Adamson, Peter J. Houghton, William D. Tap, Danny R. Welch, Patricia S. Steeg, Glenn Merlino, Poul H.B. Sorensen, Paul Meltzer, David G. Kirsch, Katherine A. Janeway, Brenda Weigel, Lor Randall, Stephen J Withrow, Melissa Paoloni, Rosandra Kaplan, Beverly A. Teicher, Nita L. Seibel, Malcolm Smith, Aykut Üren, Shreyaskumar R. Patel, Jeffrey Trent, Sharon A. Savage, Lisa Mirabello, Denise Reinke, Donald A. Barkaukas, Mark Krailo, Mark Bernstein
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4200–4209.
https://doi.org/10.1158/1078-0432.CCR-13-2574
Published: 13 August 2014
View article titled, Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Open the PDF for Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma in another window
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6058–6064.
https://doi.org/10.1158/1078-0432.CCR-11-3251
Published: 06 November 2012
View article titled, Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6011–6022.
https://doi.org/10.1158/1078-0432.CCR-11-3284
Published: 06 November 2012
View article titled, A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Julia Glade Bender, Susan M. Blaney, Scott Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice Chen, Brenda Weigel, Peter C. Adamson, Julie R. Park
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5081–5089.
https://doi.org/10.1158/1078-0432.CCR-12-0078
Published: 16 September 2012
View article titled, A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031

Soheil Meshinchi, Stephen P. Hunger, Richard Aplenc, Peter C. Adamson, J. Milburn Jessup
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1547–1554.
https://doi.org/10.1158/1078-0432.CCR-11-2205
Published: 14 March 2012
View article titled, Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031
Open the PDF for Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031 in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

Steven G. DuBois, Suzanne Shusterman, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Bing Wu, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Holcombe E. Grier, Peter C. Adamson, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5113–5122.
https://doi.org/10.1158/1078-0432.CCR-11-0237
Published: 31 July 2011
View article titled, Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study in another window
Journal Articles

Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report

Jack M. Su, Xiao-Nan Li, Patrick Thompson, Ching-Nan Ou, Ashish M. Ingle, Heidi Russell, Ching C. Lau, Peter C. Adamson, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 589–597.
https://doi.org/10.1158/1078-0432.CCR-10-0738
Published: 01 February 2011
View article titled, Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report
Open the PDF for Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report in another window
Journal Articles

Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

Shana Jacobs, Elizabeth Fox, Mark Krailo, Gwen Hartley, Fariba Navid, Leonard Wexler, Susan M. Blaney, Anne Goodwin, Wendy Goodspeed, Frank M. Balis, Peter C. Adamson, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 750–754.
https://doi.org/10.1158/1078-0432.CCR-09-1906
Published: 14 January 2010
View article titled, Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Open the PDF for Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group in another window
Journal Articles

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Molly E. Fouts, Diane Medina, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1111–1115.
https://doi.org/10.1158/1078-0432.CCR-07-4097
Published: 15 February 2008
View article titled, A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study

Erin Cooney-Qualter, Mark Krailo, Anne Angiolillo, Rashid A. Fawwaz, Gregory Wiseman, Lauren Harrison, Virginia Kohl, Peter C. Adamson, Janet Ayello, Carmella vande Ven, Sherrie L. Perkins, Mitchell S. Cairo
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5652s–5660s.
https://doi.org/10.1158/1078-0432.CCR-07-1060
Published: 17 September 2007
View article titled, A Phase I Study of <sup>90</sup>Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study
Open the PDF for A Phase I Study of <sup>90</sup>Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study in another window
Journal Articles

A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study

Brenda J. Weigel, Susan M. Blaney, Joel M. Reid, Stephanie L. Safgren, Rochelle Bagatell, John Kersey, Joseph P. Neglia, S. Percy Ivy, Ashish M. Ingle, Luke Whitesell, Richard J. Gilbertson, Mark Krailo, Matthew Ames, Peter C. Adamson
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1789–1793.
https://doi.org/10.1158/1078-0432.CCR-06-2270
Published: 15 March 2007
View article titled, A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Open the PDF for A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study in another window
Journal Articles

A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study

Terzah M. Horton, Debananda Pati, Sharon E. Plon, Patrick A. Thompson, Lisa R. Bomgaars, Peter C. Adamson, Ashish M. Ingle, John Wright, Adam H. Brockman, Martin Paton, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1516–1522.
https://doi.org/10.1158/1078-0432.CCR-06-2173
Published: 01 March 2007
View article titled, A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Open the PDF for A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study in another window
Journal Articles

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Kysa Meek, Anne Goodwin, Wendy Goodspeed, Marie Kromplewski, Molly E. Fouts, Diane Medina, Steve Y. Cho, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (16): 4882–4887.
https://doi.org/10.1158/1078-0432.CCR-06-0534
Published: 16 August 2006
View article titled, A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini, Jacek Gan, Adam G. Sternberg, Jens Eickhoff, Robert C. Seeger, Katherine K. Matthay, C. Patrick Reynolds, Clare Twist, Mark Krailo, Peter C. Adamson, Ralph A. Reisfeld, Stephen D. Gillies, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1750–1759.
https://doi.org/10.1158/1078-0432.CCR-05-2000
Published: 21 March 2006
View article titled, A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
Open the PDF for A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group in another window
Journal Articles

The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development

J. Carl Panetta, Lisa C. Iacono, Peter C. Adamson, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5068–5077.
Published: 12 November 2003
View article titled, The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development
Open the PDF for The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development in another window
Journal Articles

Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3646–3657.
Published: 01 December 2002
View article titled, Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle>
Open the PDF for Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle> in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of 9- cis -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study

Peter C. Adamson, Brigitte C. Widemann, Gregory H. Reaman, Nita L. Seibel, Robert F. Murphy, Andrea F. Gillespie, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3034–3039.
Published: 01 October 2001
View article titled, A Phase I Trial and Pharmacokinetic Study of 9- <em>cis</em> -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: <subtitle>A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study</subtitle>
Open the PDF for A Phase I Trial and Pharmacokinetic Study of 9- <em>cis</em> -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: <subtitle>A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study</subtitle> in another window